The Aurora Kinase A polymorphisms are not associated with recurrencefree survival in prostate cancer patients

Jerry Jaboin, Natalie L. Ausborn, Misun Hwang, Heidi Chen, Kenneth J. Niermann, Nicholas J. Giacalone, Regina Courtney, Qiuyin Cai, Bo Lu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The purpose of this study was to investigate the association between haplotype-tagging single nucleotide polymorphisms (SNPs) within the Aurora Kinase A (AURKA) gene and prostate cancer outcomes in patients with clinically localized prostate cancer. Methods: Four intronic haplotype-tagging SNPs within the AURKA gene were individually selected and examined in regard to their influence on clinical outcomes in 212 patients who underwent radical prostatectomy as first-line treatment. Haplotype-tagging SNPs were selected using the ABI SNP Browser to cover SNPs with an r2 of 0.90 or greater in the AURKA gene with a minor allele frequency of at least 0.25. Results: In our study, a log-rank univariate analysis was performed to identify significant associations between probability of recurrence-free survival or disease-free survival and known prognostic indicators as well as AURKA genotypes. The prognostic indicators Gleason grade, surgical margin, extracapsular extension, and disease stage were associated with recurrence-free survival (all p<0.001). Only Gleason grade was associated with disease-free survival (p<0.001). No associations were found for the SNPs rs1468055, rs8117896, rs2064863, and rs1468056 analyzed for either RFS (p=0.7213, p=0.5140, p=0.0714, p=0.4731, respectively) or DFS (p=0.3282, p=0.1909, p=0.4111, p=0.5014, respectively). Conclusions: This study demonstrates no evidence for intronic AURKA SNPs in predicting recurrence-free survival in patients with prostate cancer.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalJournal of Cancer Science and Therapy
Volume4
Issue number2
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Aurora Kinase A
Single Nucleotide Polymorphism
Prostatic Neoplasms
Survival
Haplotypes
Recurrence
Disease-Free Survival
Genes
Prostatectomy
Gene Frequency
Genotype

Keywords

  • Aurora kinase A
  • Prostate cancer
  • Recurrence-free survival
  • Single nucleotide polymorphism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The Aurora Kinase A polymorphisms are not associated with recurrencefree survival in prostate cancer patients. / Jaboin, Jerry; Ausborn, Natalie L.; Hwang, Misun; Chen, Heidi; Niermann, Kenneth J.; Giacalone, Nicholas J.; Courtney, Regina; Cai, Qiuyin; Lu, Bo.

In: Journal of Cancer Science and Therapy, Vol. 4, No. 2, 2012, p. 16-22.

Research output: Contribution to journalArticle

Jaboin, Jerry ; Ausborn, Natalie L. ; Hwang, Misun ; Chen, Heidi ; Niermann, Kenneth J. ; Giacalone, Nicholas J. ; Courtney, Regina ; Cai, Qiuyin ; Lu, Bo. / The Aurora Kinase A polymorphisms are not associated with recurrencefree survival in prostate cancer patients. In: Journal of Cancer Science and Therapy. 2012 ; Vol. 4, No. 2. pp. 16-22.
@article{9f7452f5ff1849249538951a75d0a58f,
title = "The Aurora Kinase A polymorphisms are not associated with recurrencefree survival in prostate cancer patients",
abstract = "Background: The purpose of this study was to investigate the association between haplotype-tagging single nucleotide polymorphisms (SNPs) within the Aurora Kinase A (AURKA) gene and prostate cancer outcomes in patients with clinically localized prostate cancer. Methods: Four intronic haplotype-tagging SNPs within the AURKA gene were individually selected and examined in regard to their influence on clinical outcomes in 212 patients who underwent radical prostatectomy as first-line treatment. Haplotype-tagging SNPs were selected using the ABI SNP Browser to cover SNPs with an r2 of 0.90 or greater in the AURKA gene with a minor allele frequency of at least 0.25. Results: In our study, a log-rank univariate analysis was performed to identify significant associations between probability of recurrence-free survival or disease-free survival and known prognostic indicators as well as AURKA genotypes. The prognostic indicators Gleason grade, surgical margin, extracapsular extension, and disease stage were associated with recurrence-free survival (all p<0.001). Only Gleason grade was associated with disease-free survival (p<0.001). No associations were found for the SNPs rs1468055, rs8117896, rs2064863, and rs1468056 analyzed for either RFS (p=0.7213, p=0.5140, p=0.0714, p=0.4731, respectively) or DFS (p=0.3282, p=0.1909, p=0.4111, p=0.5014, respectively). Conclusions: This study demonstrates no evidence for intronic AURKA SNPs in predicting recurrence-free survival in patients with prostate cancer.",
keywords = "Aurora kinase A, Prostate cancer, Recurrence-free survival, Single nucleotide polymorphism",
author = "Jerry Jaboin and Ausborn, {Natalie L.} and Misun Hwang and Heidi Chen and Niermann, {Kenneth J.} and Giacalone, {Nicholas J.} and Regina Courtney and Qiuyin Cai and Bo Lu",
year = "2012",
doi = "10.4172/1948-5956.1000105",
language = "English (US)",
volume = "4",
pages = "16--22",
journal = "Journal of Cancer Science and Therapy",
issn = "1948-5956",
publisher = "OMICS Publishing Group",
number = "2",

}

TY - JOUR

T1 - The Aurora Kinase A polymorphisms are not associated with recurrencefree survival in prostate cancer patients

AU - Jaboin, Jerry

AU - Ausborn, Natalie L.

AU - Hwang, Misun

AU - Chen, Heidi

AU - Niermann, Kenneth J.

AU - Giacalone, Nicholas J.

AU - Courtney, Regina

AU - Cai, Qiuyin

AU - Lu, Bo

PY - 2012

Y1 - 2012

N2 - Background: The purpose of this study was to investigate the association between haplotype-tagging single nucleotide polymorphisms (SNPs) within the Aurora Kinase A (AURKA) gene and prostate cancer outcomes in patients with clinically localized prostate cancer. Methods: Four intronic haplotype-tagging SNPs within the AURKA gene were individually selected and examined in regard to their influence on clinical outcomes in 212 patients who underwent radical prostatectomy as first-line treatment. Haplotype-tagging SNPs were selected using the ABI SNP Browser to cover SNPs with an r2 of 0.90 or greater in the AURKA gene with a minor allele frequency of at least 0.25. Results: In our study, a log-rank univariate analysis was performed to identify significant associations between probability of recurrence-free survival or disease-free survival and known prognostic indicators as well as AURKA genotypes. The prognostic indicators Gleason grade, surgical margin, extracapsular extension, and disease stage were associated with recurrence-free survival (all p<0.001). Only Gleason grade was associated with disease-free survival (p<0.001). No associations were found for the SNPs rs1468055, rs8117896, rs2064863, and rs1468056 analyzed for either RFS (p=0.7213, p=0.5140, p=0.0714, p=0.4731, respectively) or DFS (p=0.3282, p=0.1909, p=0.4111, p=0.5014, respectively). Conclusions: This study demonstrates no evidence for intronic AURKA SNPs in predicting recurrence-free survival in patients with prostate cancer.

AB - Background: The purpose of this study was to investigate the association between haplotype-tagging single nucleotide polymorphisms (SNPs) within the Aurora Kinase A (AURKA) gene and prostate cancer outcomes in patients with clinically localized prostate cancer. Methods: Four intronic haplotype-tagging SNPs within the AURKA gene were individually selected and examined in regard to their influence on clinical outcomes in 212 patients who underwent radical prostatectomy as first-line treatment. Haplotype-tagging SNPs were selected using the ABI SNP Browser to cover SNPs with an r2 of 0.90 or greater in the AURKA gene with a minor allele frequency of at least 0.25. Results: In our study, a log-rank univariate analysis was performed to identify significant associations between probability of recurrence-free survival or disease-free survival and known prognostic indicators as well as AURKA genotypes. The prognostic indicators Gleason grade, surgical margin, extracapsular extension, and disease stage were associated with recurrence-free survival (all p<0.001). Only Gleason grade was associated with disease-free survival (p<0.001). No associations were found for the SNPs rs1468055, rs8117896, rs2064863, and rs1468056 analyzed for either RFS (p=0.7213, p=0.5140, p=0.0714, p=0.4731, respectively) or DFS (p=0.3282, p=0.1909, p=0.4111, p=0.5014, respectively). Conclusions: This study demonstrates no evidence for intronic AURKA SNPs in predicting recurrence-free survival in patients with prostate cancer.

KW - Aurora kinase A

KW - Prostate cancer

KW - Recurrence-free survival

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84858974930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858974930&partnerID=8YFLogxK

U2 - 10.4172/1948-5956.1000105

DO - 10.4172/1948-5956.1000105

M3 - Article

AN - SCOPUS:84858974930

VL - 4

SP - 16

EP - 22

JO - Journal of Cancer Science and Therapy

JF - Journal of Cancer Science and Therapy

SN - 1948-5956

IS - 2

ER -